It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective new treatment for inflammatory skin conditions such as rosacea. Skin cells called ...
ACUD-1 is under clinical development by Accuitis and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success rate (PTSR) indication ...
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...